Searched for
GLIPTIN
USV in talks with Novartis to buy Jalra Trademark for Rs. 200 CroreMumbai-based drugmaker USV Pvt Ltd is in advanced discussions to acquire the trademark for antidiabetes drug Jalra from Novartis for a deal...- Mega diabetes drug to be cheaper soonWith Novartis losing patent protection for Vildagliptin in December, the cost of therapy is expected to reduce by over 50%.
- Cipla to market Novartis, and J&J’s products, while Alkem partners Dong A of South KoreaAlkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...
- Exports major contributor to API revenues: Sushil Suri, Morepen LabsThe second growth which is coming from in the domestic market is from home diagnostics.
- Now, cut treatment cost by 80 per cent with new anti-diabetes drugThe economic burden of diabetes is high in India as most patients pay out-of-pocket, and due to lack of medical reimbursement.
- New diabetes drug cuts cost by 80%A completely new drug in the 'gliptin' family has disrupted the anti-diabetes market by lowering the cost of therapy for patients by 80%.
- Mankind Pharma to invest Rs 200 crore to open 2 plants by mid-2016Mankind Pharma will invest Rs 200 crore to open two manufacturing plants in the country by the middle of 2016 as part of its expansion plan...
- Mankind pharma joins the anti-diabetic drug warIndia's anti-diabetic market is one of the fastest growing therapy segments, with a growth exceeding 25% at Rs 7638 crore, according to the...
- Mankind Pharma launches diabetes drug 'Dynaglipt'Mankind Pharma has launched an anti-diabetic product 'Dynaglipt' targeting the middle class and rural diabetic patients.
- Zydus launches Tenglyn tablets in Indian marketDrug firm Zydus Cadila has launched its generic Tenglyn tablets belonging to new class of oral anti-diabetic treatment drugs, Gliptins, in ...
- Cadila crashes the gliptin market with 'most affordable anti diabetic drug'Tenglyn, is a product belonging to a new class of drugs called gliptins, a segment that has witnessed the most aggressive growth among all ...
- Glenmark to launch 10-12 new products in India, eyes 18-20 per cent growthGlenmark Pharmaceuticals proposes to launch 10-12 new products in the domestic market during the current financial year (2015-16) and hopes...
- Glenmark expecting USFDA nod for 4-6 products this fiscalGlenmark Pharmaceuticals is expecting approvals for four to six new products during the fiscal from the US Food and Drug Administration (US...
- Lifestyle and death: Yoga is just a small step in countering Big Food and Big PharmaIndeed, recent studies show that India is undergoing an ‘epidemiological transition’ consistent with lifestyle changes.
- New medicine could help diabetics save Rs 10,000 per yearA new anti-diabetes drug from the 'gliptin' family soon to be launched in India promises to lower treatment cost for patients by 55-60%.
- Glenmark's anti-diabetes drugs shake up Indian anti-diabetes marketThe company has raked in Rs 16 crore in just 8 months since drug was launched.
- Drug makers accuse V Mohan of possible conflict of interest in getting diabetes drug Pioglitazone bannedIn January this year, Mohan had written a letter to the Prime Minister’s Office, detailing the risks of bladder cancer caused by the prolon...
- Diabetes drug ban to help companies like USV, Sun Pharma, LupinIn the wake of a government ban on top-selling diabetes drug, pioglitazone , the volumes are expected to shift to other classes such as fir...
- Merck unit sues Glenmark Pharmaceuticals for infringing patent on diabetes drugsA unit of US drugmaker Merck & Co sued India's Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs.
- DIPP for extending provision of Compulsory Licences beyond cancer drugsThe move will drastically reduce prices of key drugs, but at the same time, jeopardise the plans of multinational drug companies.
Load More
